Seizures clinical trials
The registry lists 766 studies for Seizures across more than 10 countries. 136 are recruiting or about to start. 262 of them are mainly about Seizures (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 3 narrower conditions too, such as Status Epilepticus: 898 studies, 168 open.
ClinicalTrials.gov finds 1,472 studies for Seizures. How that becomes 766 here
This page counts the studies the registry files under Seizures, and those it files under no condition that list Seizuresthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count
- 1,472Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
- −126Filed under a narrower condition, counted on its own pageStatus Epilepticus 91 · Seizures, Febrile 20 · Psychogenic Nonepileptic Seizures 13
- −93List Seizures as a condition, but the registry did not file them under itMost often written as “Epilepsy; Seizure” (17), “Seizure Disorder” (10), and “Neonatal Seizure” (8). The registry filed 2 of them under no condition at all, and the others under other conditions only, most often Epilepsy (65) and Epilepsies, Partial (8).
- −487Match it another way305 name it in the title, 62 in a keyword, and 120 by a synonym or other text the search reads.
- 766The count on this page52 of them list Seizures in their own words; the registry filed them under no condition.
Get an email when these change. Save the Seizures studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Neurological Disorders and Stroke (NINDS) (32) · Eisai Inc. (21) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (19) · SK Life Science, Inc. (15) · UCB Pharma (14) · GlaxoSmithKline (14) · Assiut University (12) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (12)
What is being tested here
Drugs under test in Seizures studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Levetiracetam | 7 | 19 | 48 |
| RAP-219 | 3 | 2 | 4 |
| SPN-817 | 3 | 0 | 3 |
| Cannabidiol | 2 | 5 | 12 |
| Tranexamic Acid | 2 | 2 | 4 |
| XEN1101 | 2 | 3 | 3 |
| Methylphenidate | 2 | 0 | 3 |
| Clemizole hydrochloride | 2 | 2 | 2 |
| Perampanel | 1 | 4 | 17 |
| Carisbamate | 1 | 9 | 9 |
Drug classes tested here Stimulants 2 open · Serotonin receptor agonists 1 open · Anxiolytics 16 · SSRIs 8
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Nov 2026An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome · Phase 3 · Epygenix
- Dec 2026A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy · Phase 3 · Biohaven Therapeutics Ltd.
- Dec 2026A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety · Phase 3 · Praxis Precision Medicines
- Dec 2026Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment · Phase 3 · Novartis Pharmaceuticals
- Dec 2026A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) · Phase 3 · Longboard Pharmaceuticals
- Jan 2027Levetiracetam for Seizure Prevention After Brain Tumor Surgery · Phase 3 · Beijing Tiantan Hospital
- Feb 2027Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults · Phase 3 · SK Life Science, Inc.
- Mar 2027A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures · Phase 3 · UCB Biopharma SRL
- Apr 2027A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome · Phase 3 · Epygenix
- Nov 2027A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. · Phase 3 · Zogenix, Inc.
Who these studies take
Of the 94 Seizures studies recruiting now, 36 (38%) set no upper age limit and 45 (48%) stop at 75 or younger. 39 (41%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 18 (19%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 27 (29%) | 27 (29%) |
| 18 | 79 (84%) | 79 (84%) |
| 30 | 75 (80%) | 75 (80%) |
| 40 | 76 (81%) | 76 (81%) |
| 50 | 76 (81%) | 76 (81%) |
| 65 | 69 (73%) | 69 (73%) |
| 75 | 58 (62%) | 58 (62%) |
| 85 | 47 (50%) | 47 (50%) |
Across all 766 studies, recruiting or not: 51% stop at 75 or younger and 41% at 65; 53% take children; 2% are for women only and 1% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Seizures studies take
Of 51 phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 36 mo26–56 · 16 studies | — | — |
| Phase 2 | 40 mo20–58 · 35 studies | — | — |
| Phase 3 | 54 mo33–79 · 51 studies | 54 mo33–79 · 43 studies | — |
| Phase 4 | 28 mo20–42 · 26 studies | — | — |
| Interventional, no phase | 32 mo22–51 · 83 studies | — | 33 mo22–53 · 74 studies |
| Observational | 38 mo18–96 · 80 studies | 29 mo18–39 · 27 studies | 70 mo18–… · 53 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 11, 2026.
Started recruiting2
- HOBSCOTCH-YOUTH and Young AdultsNov 2, 2026NCT07735715
- Oxygen Toxicity: Mechanisms in HumansOct 21, 2026NCT05761756
Results posted1
Stopped1
- Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic EpilepsiesTerminatedOct 14, 2026NCT06700811
Studies
Recruiting first, then most recently updated. Showing 50 of 766. Browse all 766 → or search them.
- Study of Direct Brain Recording and Stimulation for Memory EnhancementEnrolling by invitationNCT040950261 country
- Tumor Related EpilepsyRecruitingNCT026393251 country
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1RecruitingNCT07563881Phase 34 countries
- Study of Electrocardiogram (ECG) Safety of Sezaby in Neonatal SeizuresNot yet recruitingNCT07923734Phase 41 country
- A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresRecruitingNCT05077904Phase 313 countries
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal SeizuresRecruitingNCT07594119Phase 32 countries
- Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and AdultsRecruitingNCT05219617Phase 316 countries
- A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Cannabidiol Capsules (AVAT-121) and Epidyolex® in Healthy AdultsNot yet recruitingNCT07918469Phase 1
- Genetic Markers of Cardiovascular Disease in EpilepsyRecruitingNCT028248221 country
- Mapping of Human CognitionRecruitingNCT05989893Not applicable1 country
- An Open-label Study of XEN1101 in EpilepsyEnrolling by invitationNCT05718817Phase 325 countries
- HOBSCOTCH-YOUTH and Young AdultsRecruitingNCT07735715Not applicable1 country
- A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)RecruitingNCT05716100Phase 321 countries
- Lily's Grace Temporal InterferenceNot yet recruitingNCT07520955Not applicable1 country
- Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))RecruitingNCT05135091Phase 31 country
- Early Post-Traumatic Seizures Prevention Trial (E-PTS Trial)RecruitingNCT07072624Phase 41 country
- Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant EpilepsyRecruitingNCT02531880Phase 11 country
- Natural History of Treated Neurocysticercosis and Long-Term OutcomesRecruitingNCT000012051 country
- A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset SeizuresRecruitingNCT07233239Phase 11 country
- A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet SyndromeRecruitingNCT04462770Phase 311 countries
- High-Intensity Focused Ultrasonic Ablation of the Centromedian Thalamic Nucleus for Treatment of Medically Refractory Generalized Epilepsy in Patients Ages 18 Years to 89 YearsNot yet recruitingNCT07803692Not applicable1 country
- SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresEnrolling by invitationNCT07141329Phase 22 countries
- Investigating Epilepsy: Screening and EvaluationRecruitingNCT034788521 country
- Oxygen Toxicity: Mechanisms in HumansRecruitingNCT05761756Not applicable1 country
- Ear-Seizure Detection (EarSD) StudyRecruitingNCT06598189Not applicable1 country
- A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)Enrolling by invitationNCT06908226Phase 317 countries
- Clinical and Electrographic Changes in Responsive Neurostimulation System (RNS) Patients With Acupuncture TreatmentRecruitingNCT04677751Not applicable1 country
- An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut SyndromeRecruitingNCT05066217Phase 310 countries
- The TTM and ASM TrialNot yet recruitingNCT07835802Phase 11 country
- Pharmacological Modulation of Brain Oscillations in Memory ProcessingRecruitingNCT05594017Early Phase 11 country
- A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)Not yet recruitingNCT06792500Phase 1/21 country
- RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresRecruitingNCT06798896Phase 25 countries
- Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)Not yet recruitingNCT07680322Phase 21 country
- Cholinergic Enhancement of ThetaNot yet recruitingNCT07228338Early Phase 11 country
- Multi-level Approach of Brain Activity Using Intracranial Electrodes in Epileptic PatientsRecruitingNCT04653012Not applicable1 country
- Modulating Movement Intention Via Cortical StimulationRecruitingNCT03233399Not applicable1 country
- Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and WearablesRecruitingNCT07012148Early Phase 11 country
- A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresEnrolling by invitationNCT05076617Phase 312 countries
- Acute Effects of Focused Ultrasound Modulation on EEG Behavior in Status Epilepticus PatientsRecruitingNCT05784805Not applicable1 country
- Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in EpilepsyRecruitingNCT02216500Not applicable1 country
- A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant EpilepsyRecruitingNCT06388707Phase 1/21 country
- Prospective Natural History Study of POLG DiseaseRecruitingNCT077758729 countries
- Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset SeizuresNot yet recruitingNCT06534502Phase 41 country
- SeizEAR Safety StudyRecruitingNCT07088835Not applicable1 country
- A Study to Investigate the Transition of Children From 'Artisanal" Cannabidiol (CBD) to EpidiolexNot yet recruitingNCT06924827Phase 41 country
- Prospective Study of Eslicarbazepine in Adults With Focal-Onset SeizuresRecruitingNCT077933961 country
- Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain MetastasesRecruitingNCT07130786Phase 21 country
- Epileptiform Potential of Fully Immersive Virtual RealityNot yet recruitingNCT07451093Not applicable1 country
- Retraining and Control Therapy (ReACT): Sense of Control and Symptom Expectations as Targets of a Treatment for PNESRecruitingNCT05096273Not applicable1 country
- Outcomes After Planned Discontinuation of AntiSeizure MedicationRecruitingNCT07750496Phase 41 country